Syros Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Multiple Upcoming Clinical Milestones for Its First-in-Class Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. META

Go back to Syros Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Multiple Upcoming Clinical Milestones for Its First-in-Class Programs

Syros Pharmaceuticals (SYRS) Misses Q4 EPS by 5c

March 7, 2019 7:35 AM EST

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q4 EPS of ($0.54), $0.05 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $893 thousand versus the consensus estimate of $390 thousand.

Our accomplishments in 2018 position us for multiple potential clinical milestones in 2019 and 2020 that bring us closer to our vision of... More